LBO1 DORIS remission in patients with SLE treated with anifrolumab or placebo during the 4-year TULIP-LTE trial: post hoc analysis

• Richard Furie,
• Raj Tummala,
• Kenneth Kalunian,
• Eric Morand,
• Gabriel Abreu,
• Ronald van Vollenhoven,
• Catharina Lindholm,
• Hussein Al-Mossawi

Affiliations

Richard Furie

3Division of Rheumatology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, USA

Raj Tummala

BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA

Kenneth Kalunian

4Division of Rheumatology, Allergy and Immunology, University of California San Diego, CA, USA

Eric Morand

8School of Clinical Sciences, Monash University, Melbourne, VIC, Australia

Gabriel Abreu

Biometrics, Late Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden

Ronald van Vollenhoven

3Amsterdam Rheumatology and Immunology, Amsterdam, The Netherlands

Catharina Lindholm

BioPharmaceuticals R&D, AstraZeneca, Goteborg, Sweden

Hussein Al-Mossawi

Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK